Back to results
US 2017/0304272 A1Published application
Isoxazole derivatives as fxr agonists and methods of use thereof
AssigneeEnanta Pharmaceuticals, Inc.
InventorsYat Sun Or, Bin Wang, Xuechao Xing, Ruichao Shen, Brett Granger, Jun Ma, Jing He, Yong He, Jiang Long, Guoqiang Wang
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
Claims23
A compound represented by Formula I, or a pharmaceutically acceptable salt thereof:
- wherein:
- R1 is hydrogen, halogen, cyano, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C6 cycloalkyl or optionally substituted 3- to 6-membered heterocycloalkyl;
- R2 is an optionally substituted aryl, optionally substituted heteroaryl, optionally substitutedarylalkyl or optionally substituted heteroarylalkyl;
- X1, X2, X3, and X4 are independently selected from N or C(Y);
- wherein Y is selected from hydrogen, halo, cyano, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, heterocycloalkyl, haloalkyl, alkoxy, or haloalkoxy;
- is aryl, heterocyclic, heteroaryl, bicyclic fused arylheterocyclic or bicyclic fused heteroarylheterocyclic, wherein said aryl, heterocyclic, heteroaryl, bicyclic fused arylheterocyclic or bicyclic fused heteroarylheterocyclic is optionally substituted with one or two substituents independently selected from optionally substituted —C1-C8 alkyl, halo, and halo-C1-C8-alkyl;
- R3 is
- R4, and R5 are independently selected from the group consisting of:
- 1) Hydrogen;
- 2) Optionally substituted —C1-C8 alkyl;
- 3) Optionally substituted —C2-C8 alkenyl;
- 4) Optionally substituted —C2-C8 alkynyl;
- and
- 5) Optionally substituted —C3-C8 cycloalkyl;
- R6 is selected from the group consisting of:
- 1) Optionally substituted —C1-C8 alkyl;
- 2) Optionally substituted —C2-C8 alkenyl;
- 3) Optionally substituted —C2-C8 alkynyl;
- 4) Optionally substituted —C3-C8 cycloalkyl;
- 5) Optionally substituted aryl;
- 6) Optionally substituted arylalkyl;
- 7) Optionally substituted 3- to 8-membered heterocycloalkyl;
- 8) Optionally substituted heteroaryl;
- 9) Optionally substituted heteroarylalkyl;
- and
- 10) NR7R8;
- wherein R7 and R8 are each independently selected from hydrogen, optionally substituted —C1-C8 alkyl, optionally substituted —C2-C8 alkenyl, optionally substituted —C2-C8 alkynyl, optionally substituted —C3-C8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted 3- to 8-membered heterocycloalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or R7 and R8 are taken together with the nitrogen atom which they are attached to form an optionally substituted heterocyclic ring.
24 more elements
(canceled)
Dependencies are inferred from the claim text.